Order Article Reprints

Puengel T, Weber B, Wirtz TH, Buendgens L, Loosen SH, Geisler L, Özdirik B, Hamesch K, Jhaisha SA, Brozat JF, et al. Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients. Diagnostics. 2022; 12(1):62. https://doi.org/10.3390/diagnostics12010062

Puengel, Tobias, Beate Weber, Theresa H. Wirtz, Lukas Buendgens, Sven H. Loosen, Lukas Geisler, Burcin Özdirik, Karim Hamesch, Samira Abu Jhaisha, Jonathan F. Brozat, and et al. 2022. "Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients" Diagnostics 12, no. 1: 62. https://doi.org/10.3390/diagnostics12010062

Puengel, T., Weber, B., Wirtz, T. H., Buendgens, L., Loosen, S. H., Geisler, L., Özdirik, B., Hamesch, K., Jhaisha, S. A., Brozat, J. F., Hohlstein, P., Eisert, A., Yagmur, E., Trautwein, C., Tacke, F., & Koch, A. (2022). Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients. Diagnostics, 12(1), 62. https://doi.org/10.3390/diagnostics12010062